When: MACD histogram compressing

Then: Satisfies momentum confirmation (OR condition)

TRIM AT UPPER END (35-40%), TIGHTER STOP (142.50), RIGOROUS RE-ENTRY TRIGGERS, TIME-BOUNDED CORE HOLD TO Q3 CATALYST

• Trim size should be 35-40%, not 25% - 60% core preserved for Q3 catalyst
• Stop at 142.50, not 141.50 - 1.6% risk on remaining core, just below Sep 11 intraday low of 143.68
• Re-entry requires three conditions: reclaim 148 with volume at 9-10M shares, RSI above 55, MACD histogram compressing
• Core hold tied to Q3 earnings catalyst - hard decision date, not open-ended
• Aggressive analyst's 18% downside using 200 SMA at 118.72 is cherry-picked - 50 SMA at 136.35 implies only 6% downside
• M&A integration thesis is overcooked - Merck has multi-decade track record (Schering-Plough, Acceleron, Prometheus, Cubist)
• Forward P/E of 15.17x on $9.55 EPS already prices earnings recovery
• Yield disadvantage (2.36% vs 5% Treasuries) offset by dividend growth, 86% capital appreciation from $77.58 low, and tax treatment
• Restrictive macro: 10-year above 5%, 94% probability of no Fed cuts in 2026
• MACD crossed bearish with histogram accelerating negative at -1.48
• Bullish long-term stack (50 SMA above 200 SMA, Aug 19 breakout on 32.8M shares) supports core but not full exposure
• Defensive fundamentals: 0.226 beta, 75.9% gross margin, $15B trailing free cash flow provide floor

→ vs aggressive: Uses 200 SMA at 118.72 for 18% downside but ignores the 50 SMA at 136.35 which implies only 6% downside - cherry-picking extreme targets is fear-mongering

→ vs aggressive: Entire trim plan depends on MRK bouncing to 148-150, but if price goes straight to 141.50 without tagging that range, trim window never opens - same waiting he accuses neutral analyst of

→ vs aggressive: M&A integration disaster thesis is low-probability, high-conviction bet - not conservative risk management, it's directional speculation

→ vs neutral: Holding full position size during bearish MACD crossover (-1.48 histogram), restrictive macro (10-year 5%, 94% no Fed cuts 2026), is volunteering for drawdown

→ vs neutral: Buy trigger at 140 may never fire if MRK gaps down to 138 on negative catalyst - leaves larger loss than trim would have prevented

→ vs neutral: Bullish long-term stack is reason to keep core, not full position - can be bullish long-term and defensive short-term simultaneously

Trim 30-35% of MRK position in tranches at 148-150; retain 65% core with stop at 141.50; re-enter on 2 of 3 technical signals with mandatory volume confirmation; hold through Q3 catalyst with data-driven exit rules.

• Current price: 144.85; trim window target: 148 to 150; recommended scale-out: 20% at 148, 15% at 150, hold 65% core
• Stop level: 141.50 (below September 11 intraday low of 143.68; ATR is 3.70 requiring at least 2 dollars of cushion)
• Re-entry requires: price reclaim 148 on volume above 9 million shares (mandatory) plus either RSI above 55 OR MACD histogram compressing (one of two)
• 30-35% trim is the sweet spot: 25% too timid leaving excessive exposure, 40% too aggressive given underlying franchise quality
• Beta: 0.226; TTM gross margin: 75.9%; TTM free cash flow: 15 billion; these structural supports argue for meaningful core retention
• Q4 2025 gross margin of 66.2% versus 75.9% TTM is quarterly noise, not structural break; target recovery toward 70%
• Macro backdrop (10-year above 5%, 94% probability of no Fed cuts, 10% recession odds) supports defensive pharma relative outperformers given low beta
• Stock is 7.5% off 52-week high, below 10 EMA, below Bollinger middle, below VWAP—competitive discount partially priced
• Trim window depends on price rallying to 148-150; if MRK goes straight to 141.50 without tagging 148, window closes and position faces drawdown without trim benefit
• Hold period tied to Q3 earnings catalyst with decision triggers: gross margin recovery toward 70%, constructive pipeline commentary, no ivonescimab escalation

→ vs aggressive: Risk-reward framing is overstated; 200 SMA at 118.72 represents a deep tail scenario, not realistic downside; actual structural support is 50 SMA at 136.35 (about 6% below current)

→ vs aggressive: Trim window of 148-150 is too optimistic about price cooperation; if MRK goes straight to 141.50 without tagging 148, the trim opportunity disappears entirely

→ vs aggressive: M&A integration thesis is a directional bet, not risk management; Schering-Plough 2009 merger created disruption but also unlocked franchise expansion including Keytruda build

→ vs aggressive: Low beta (0.226) means MRK should outperform relatively in defensive regime; aggressive analyst ignores this reason to maintain core exposure

→ vs aggressive: 52-week high at 156 is the same distance as 50 SMA at 136.35; framing 156 as upside while ignoring 136 as downside is selective framing, not asymmetry

→ vs conservative: Yield disadvantage argument misses marginal investor math; anyone buying at 145 faces 2.36% yield versus 5% risk-free Treasury, which is genuinely worse than two years ago

→ vs conservative: Tightening stop from 141.50 to 142.50 is too tight; ATR of 3.70 means 1.5-2 dollar intraday swings are normal noise, and 142.50 stop gets chopped out by volatility the analyst is trying to manage

→ vs conservative: Three-part re-entry trigger (all three conditions simultaneously) is a recipe for paralysis; will miss re-entry while stock runs to 160 without perfect alignment